These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26044891)

  • 1. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.
    Cheah CY; Orlowski RZ; Manasanch EE; Oo TH
    Ann Hematol; 2015 Sep; 94(9):1605-7. PubMed ID: 26044891
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.
    Elessa D; Talbot A; Lombion N; Harel S; Galicier L; Veyradier A; Joly B; Andreoli A; Rigaudeau S; Azoulay É; Coppo P; Royer B; Arnulf B
    Br J Haematol; 2020 Jan; 188(2):338-340. PubMed ID: 31840243
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
    Amraoui K; Belhadj K; Maître B; Jannière-Nartey C; Dupuis J
    Eur Respir Rev; 2013 Mar; 22(127):93-5. PubMed ID: 23457172
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma.
    Xiao X; Zhong HY; Zhang GS; Deng MY
    J Thromb Thrombolysis; 2013 Nov; 36(4):422-3. PubMed ID: 23397497
    [No Abstract]   [Full Text] [Related]  

  • 5. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Dasanu CA; Bockorny B; Alexandrescu DT
    J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide-induced photosensitivity.
    Pérez-Paredes MG; Rodríguez-Prieto MÁ; Ruiz-González I; Valladares-Narganes LM
    Photodermatol Photoimmunol Photomed; 2013 Dec; 29(6):334-6. PubMed ID: 24112407
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thalidomide treatment in multiple myeloma].
    Hattori Y
    Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
    Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
    Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Desensitization to lenalidomide].
    Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
    Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
    Sanchorawala V; Shelton AC; Zeldis JB; Seldin DC
    Am J Hematol; 2013 Aug; 88(8):719. PubMed ID: 23650113
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
    Kapoor P; Kumar S; Mandrekar SJ; Laumann KM; Dispenzieri A; Lacy MQ; Dingli D; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV; Witzig TE
    Leukemia; 2011 Jul; 25(7):1195-7. PubMed ID: 21468037
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
    Nardone B; Wu S; Garden BC; West DP; Reich LM; Lacouture ME
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):424-9. PubMed ID: 23769670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and second malignancies in myeloma patients.
    Pratt G
    Lancet Oncol; 2014 Mar; 15(3):253-4. PubMed ID: 24525201
    [No Abstract]   [Full Text] [Related]  

  • 17. Encephalopathy in a patient after long-term treatment with thalidomide.
    Sohlbach K; Heinze S; Shiratori K; Sure U; Pagenstecher A; Neubauer A
    J Clin Oncol; 2006 Oct; 24(30):4942-4. PubMed ID: 17050881
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombotic thrombocytopenic purpura associated with multiple myeloma.
    Alpay N; Uzun S; Bahat G; Yavuz S; Erten N; Tascioglu C
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):439-41. PubMed ID: 18600096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
    de la Rubia J; Roig M; Ibáñez A; García I; Vera JA; Aguilar C; del Campo R; González N; Martínez R; Palomera L; Picón I; Rodríguez JN; Sanz MA
    Eur J Haematol; 2010 Oct; 85(4):363-5. PubMed ID: 20662900
    [No Abstract]   [Full Text] [Related]  

  • 20. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.